Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Emerging therapies for inv(16) AML

Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan

Blood (2021) 137 (19): 2579–2584.

https://doi.org/10.1182/blood.2020009933

Published: 2021

Journal Articles

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia

AHyun Choi, Anuradha Illendula, John A. Pulikkan, Justine E. Roderick, Jessica Tesell, Jun Yu, Nicole Hermance, Lihua Julie Zhu, Lucio H. Castilla, John H. Bushweller, Michelle A. Kelliher

Blood (2017) 130 (15): 1722–1733.

https://doi.org/10.1182/blood-2017-03-775536

Published: 2017

Includes: Supplemental data

Journal Articles

Nras G12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis

Liting Xue, John A. Pulikkan, Peter J. M. Valk, Lucio H. Castilla

Blood (2014) 124 (3): 426–436.

https://doi.org/10.1182/blood-2013-12-541730

Published: 2014

Includes: Supplemental data

Journal Articles

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations

John A. Pulikkan, Philomina S. Peramangalam, Viola Dengler, Phoenix A. Ho, Claude Preudhomme, Soheil Meshinchi, Maximilian Christopeit, Oliver Nibourel, Carsten Müller-Tidow, Stefan K. Bohlander, Daniel G. Tenen, Gerhard Behre

Blood (2010) 116 (25): 5638–5649.

https://doi.org/10.1182/blood-2010-04-281600

Published: 2010

Includes: Supplemental data

Journal Articles

Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia

John A. Pulikkan, Viola Dengler, Philomina S. Peramangalam, Abdul A. Peer Zada, Carsten Müller-Tidow, Stefan K. Bohlander, Daniel G. Tenen, Gerhard Behre

Blood (2010) 115 (9): 1768–1778.

https://doi.org/10.1182/blood-2009-08-240101

Published: 2010

Includes: Supplemental data

Journal Articles

Target proteins of C/EBPαp30 in AML: C/EBPαp30 enhances sumoylation of C/EBPαp42 via up-regulation of Ubc9

Mulu Geletu, Mumtaz Y. Balkhi, Abdul A. Peer Zada, Maximilian Christopeit, John A. Pulikkan, Arun K. Trivedi, Daniel G. Tenen, Gerhard Behre

Blood (2007) 110 (9): 3301–3309.

https://doi.org/10.1182/blood-2007-01-071035

Published: 2007

Includes: Supplemental data

NARROW

Emerging therapies for inv(16) AML

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia

Nras G12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations

Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia

Target proteins of C/EBPαp30 in AML: C/EBPαp30 enhances sumoylation of C/EBPαp42 via up-regulation of Ubc9

Email alerts

ASH Publications

American Society of Hematology

Emerging therapies for inv(16) AML

RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia

Nras G12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis

C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations

Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia

Target proteins of C/EBPαp30 in AML: C/EBPαp30 enhances sumoylation of C/EBPαp42 via up-regulation of Ubc9

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only